Advances in the management of chronic obstructive pulmonary disease

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 1, 2007, Pages 23-37

  Meinke, Laura ^a   Chitkara, Rajinder ^a   Krishna, Ganesh ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

agonists; Anticholinergics; COPD; Inhaled corticosteroids; Smoking cessation

Indexed keywords

1 (2 BROMOPHENYL) 3 (2 HYDROXY 4 NITROPHENYL)UREA; ACETYLCYSTEINE; ALPHA 1 ANTITRYPSIN; ALPHAGEN; AMFEBUTAMONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; CARBOCISTEINE; CORTICOSTEROID; ERDOSTEINE; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; GHRELIN; GLYCOPYRRONIUM BROMIDE; INFLIXIMAB; INTERLEUKIN 8 ANTIBODY; IPRATROPIUM BROMIDE; IPRATROPIUM BROMIDE PLUS SALBUTAMOL SULFATE; MACROLIDE; NICOTINE; OXITROPIUM BROMIDE; PLACEBO; REVATROPATE; SALBUTAMOL; SALMETEROL; THEOPHYLLINE; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VARENICLINE;

ALPHA 1 ANTITRYPSIN DEFICIENCY; ANXIETY; BRONCHIECTASIS; BRONCHIOLITIS; BRONCHODILATATION; CACHEXIA; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; COMMON COLD; CYSTIC FIBROSIS; DRUG DOSE INCREASE; DRUG HALF LIFE; EMPHYSEMA; GENE REPLACEMENT THERAPY; HUMAN; LOW DRUG DOSE; LUNG BULLA; LUNG RESECTION; LUNG TRANSPLANTATION; LUNG VOLUME; METERED DOSE INHALER; MONOTHERAPY; MUCOLYSIS; NICOTINE REPLACEMENT THERAPY; NONHUMAN; OXYGEN THERAPY; PATHOGENESIS; POWDER INHALER; REVIEW; SIDE EFFECT; SMOKING CESSATION; TACHYCARDIA; TREMOR; UNSPECIFIED SIDE EFFECT;

DISEASE MANAGEMENT; DRUGS, INVESTIGATIONAL; HUMANS; OXYGEN INHALATION THERAPY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 33846066462     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.1.23     Document Type: Review

References (148)

1. NATIONAL HEART, LUNG AND BLOOD INSTITUTE: Morbidity and Mortality; Chartbook on Cardiovascular, Lung and Blood Diseases. US Department of Health and Human Services, Public Health Service, National Institutes of Health, Bethesda, MD 1998.
2. MILLER JD, FOSTER T, BOULANGER L et al.: Direct costs of COPD in the US: an analysis of medical expenditure panel survey (MEPS) data. COPD (2005) 2:311-318.
3. MURRAY CJ, LOPEZ AD: Evidence based health policy - lessons from the Global Burden of Disease Study. Science (1996) 274:740-743.
4. NATIONAL HEART, LUNG AND BLOOD INSTITUTE: Data fact sheet, chronic obstructive pulmonary disease. NIH Publication No. 03-5229, March 2003.
5. PAUWELS RA, BUIST AS, CALVERLEY PM et al.: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO global initiative for chronic obstructive lung disease (GOLD) workshop summary. Am. J. Respir. Crit. Care Med. (2001) 163:1256-1276.
6. DISTEFANO A, CARAMORI G, RICCIARDOLO FL et al.: Cellular and molecular mechanisms in chronic obstructive pulmonary disease: an overview. Clin. Exp. Allergy (2004) 34:1156-1167.
7. AGUSTI A, MACNEE W, DONALDSON K, COSIO M: Hypothesis: does COPD have an autoimmune component? Thorax (2003) 58:832-834.
8. HOGG JC, CHU F, UTOKAPARCH S et al.: The nature of small-airway obstruction in chronic obstructive pulmonary disease. N. Engl. J. Med. (2004) 350:2645-2653.
9. HURD S, PAUWELS R: Global initiative for chronic obstructive lung diseases (GOLD). Pulm. Pharmacol. Ther. (2002) 15(4):353.
10. PAUWELS RA: National and international guidelines for COPD: the need for evidence. Chest (2000) 117:20S-22S.
11. BRITTON J, KNOX A: Helping people to stop smoking: the new smoking cessation guidelines. Thorax (1999) 54:1-2.
12. NO AUTHORS LISTED: The tobacco use and dependence clinical practice guideline panel, staff and consortium representatives. A clinical practice guideline for treating tobacco use and dependence. JAMA (2000) 283:3244-3254.
13. GONZALES D, RENNARD SI, NIDES M et al.: Varenicline: an α4β2 nicotinic acetylcholine receptor partial agonist, versus sustained-release bupropion and placebo for smoking cessation. JAMA (2006) 291(1):47-55.
14. JORENBY DE, HAYS JT, RIGOTTI NA et al.: Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, versus placebo or sustained-release bupropion for smoking cessation. JAMA (2006) 291(1):56-63.
15. TONSTAD S: Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA (2006);296:64-71.
16. O'DONNELL DE, LAM M, WEBB KA: Measurement of symptoms, lung hyperinflation and endurance during exercise in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. (1998) 158:1557-1565.
17. LIESKER JJ, WIJKSTRA PJ, TEN HACKEN NH et al.: A systematic review of the effects of bronchodilators on exercise capacity in patients with COPD. Chest (2002) 121:597-608.
18. DOLOVICH MB, AHRENS RC, HESS DR et al.: Device selection and outcomes of aerosol therapy: evidence-based guidelines. Chest (2005) 127:335-371.
19. SESTINI P, RENZONI E, ROBINSON S et al.: Short-acting β2 agonists for stable chronic obstructive pulmonary disease. Cochrane Datahase Syst Rev (2002) 4:CD001495.
20. ROSSINEN J, PARTANEN J, STENIUS-AARNIALA B et al.: Salbutamol inhalation has no effect on myocardial ischemia, arrhythmias and heart-rate variability in patients with coronary artery disease plus asthma of chronic obstructive pulmonary disease. J. Intern. Med. (1998) 243:361-366.
21. SUISSA S, ASSIMES T, ERNST P: Inhaled short acting β-agonist use in COPD and the risk of acute myocardial infarction. Thorax (2003) 58:43-46.
22. BOYD G, MORICE AH, POUNSFORD JC et al.: An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Eur. Respir. J. (1997) 10:815-821.
23. WEINER P, MAGADLE R, BERAR-YANAY N et al.: The cumulative effect of long-acting bronchodilators, exercise, and inspiratory muscle training on the perception of dyspnea in patients with advanced COPD. Chest (2000) 118:672-678.
24. AALBERS R, AYRES J, BACKER V et al.: Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial. Eur. Respir. J. (2002) 19:936-943.
25. BENHAMOU D, CUVELIER A. MUIR FJ et al.: Rapid onset of bronchodilation in COPD: a placebo-controlled study comparing formoterol (foradil aerolizer) with salbutamol (ventodisk). Respir. Med. (2001) 95:817-821.
26. CAZZOLA M, D'AMATO M, CALIFANO C et al.: Formoterol as dry powder oral inhalation compared with salbutamol metered-dose inhaler in acute exacerbations of chronic obstructive pulmonary disease. Clin. Ther. (2002) 24:595-604.
27. TASHKIN DP, COOPER CB: The role of long-acting bronchodilators in the management of stable COPD. Chest (2004) 125:249-259.
28. STOCKLEY RA, CHOPRA N, RICE L: Addition of salmeterol to existing treatment in patients with COPD: a 12 month study. Thorax (2006) 61:122-128.
29. MINETTE P, BARNES PJ: Prejunctional inhibitory muscarinic receptors on cholinergic nerves in human and guinea-pig airways. J. Appl. Physiol. (1988) 64:2532-2537.
30. BARNES PF: The pharmacological properties of tiotropium. Chest (2000) 117:63S-66S.
31. DONOHUE JF, VAN NOORD JA, BATEMAN ED et al.: a 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium, or salmeterol. Chest (2002) 122:47-55.
32. VINCKEN W VAN NOORD JA, GREEFHORST AP et al.: Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur. Respir. J. (2002) 19:209-216.
33. CASABURI R, MAHLER DA, JONES PW et al.: A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur. Respir. J. (2002) 19:217-224.
34. NIEWOEHNER DE, RICE K, COTE C et al.: Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily anticholinergic bronchodilator. A randomized trial. Ann. Intern. Med. (2005) 143:317-326.
35. BARR RG, BOURBEAU J, CAMARGO CA, RAM FS: Inhaled tiotropium for stable chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. (2005) 2:CD002876.
36. ALABASTER VA: Discovery and development of selective M3 antagonists for clinical use. Life Sci. (1997) 60:1053-1060.
37. SINGH D, CORRIS PA, SNAPE S et al.: NVA237, a once-daily inhaled antimuscarinic, provides 24 hour bronchodilator efficacy with comparable bronchodilation to albuterol in patients with moderate-to-severe COPD. Proceedings of the American Thoracic Society, Abstracts (2006) 3:A113.
38. HATTOTUWA KL, GIZYCKI MJ, ANSARI TW, JEFFERY PK, BARNES NC: The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study. Am. J. Respir. Crit. Care Med. (2002) 165:1592-1596.
39. BURGE PS, CALVERLEY PM, JONES PW et al.: Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br. Med. J. (2000) 320:1297-1303.
40. VESTBO J, SORENSEN T, LANGE P et al.: Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomized controlled trial. Lancet (1999) 353:1819-1823.
41. LUNG HEALTH STUDY RESEARCH GROUP: Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N. Engl. J. Med. (2000) 343:1902-1909.
42. PAUWELS RA, LOFDAHL CG, LAITINEN LA et al.: Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N. Engl. J. Med. (1999) 340:1948-1953.
43. ALSAEEDI A, SIN DD, McALISTER FA: The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am. J. Med. (2002) 113:59-65.
44. SORIANO JB, VESTBO J, PRIDE NB et al.: Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. Eur Respir. J. (2002) 20:819-825.
45. SIN DD, TU JV: Inhaled corticosteroids and survival in chronic obstructive pulmonary disease: does the dose matter? Eur. Respir. J. (2003) 21:260-266,
46. TORCH STUDY GROUP: The TORCH (Towards a Revolution in COPD Health) survival study protocol. Eur. Respir. J. (2004) 24:206-210.
47. NIEWOEHNER DE, ERBLAND ML, DEUPREE RH et al.: Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N. Engl. J. Med. (1999) 340:1941-1947.
48. DAVIES L, ANGUS RM, CALVERLEY PM: Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomized controlled trial. Lancet (1999) 354:456-460.
49. CHRISCHELLES E, GILDEN D, KUBISIAK J et al.: Delivery of ipratropium and albuterol combination therapy for chronic obstructive pulmonary disease: effectiveness of a two-in-one inhaler versus separate inhalers. Am. J. Manag. Care (2002) 8:902-911.
50. COMBIVENT INHALATION AEROSOL STUDY GROUP: In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone: an 85-day multicenter trial. Chest (1994) 105:1411-1419.
51. BARANIUK JN, ALI M, BRODY D et al.: Glucocorticoids induce β-2-andrenergic receptor function in human nasal mucosa. Am. J. Respir. Crit. Care Med. (1997) 155:704-710.
52. ROTH M, JOHNSON PR, FUDIGER JJ et al.: Interaction between glucocorticoids and β-2 agonists on bronchial airway smooth muscle cells through synchronized cellular signaling. Lancet (2002) 360:1293-1299.
53. HANANIA NA, DARKEN P, HORSTMAN D et al.: The efficacy and safety of fluticasone propionate (250mcg)/salmeterol (50 mcg) combined in the Diskus inhaler for the treatment of COPD. Chest (2003) 124:834-843.
54. CALVERLEY P, PAUWELS R, VESTBO J et al.: Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomized controlled trial. Lancet (2003) 361:449-456.
55. MAHLER DA, WIRE P HORSTMAN D et al.: Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. (2002) 166:1084-1091.
56. DONOHUE JF, KALBERG C, EMMETT A et al.: A short-term comparison of fluticasone propionate/salmeterol with ipratropium bromide/albuterol for the treatment of COPD. Treat Respir. Med. (2004) 3:173-181.
57. NANNINI L, CATES CJ, LASSERSON TJ, POOLE P: Combined corticosteroid and long acting β-agonist in one inhaler for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. (2004) 3:CD003794.
58. VAN NOORD JA, AUMANN JL, JANSSENS E et al.: Effects of tiotropium with and without formoterol an airflow obstruction and resting hyperinflation in patients with COPD. Chest (2006) 129(3):509-517.
59. NOCTURNAL OXYGEN THERAPY TRIAL GROUP: Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann. Intern. Med. (1980) 93:391-398.
60. TARPY SP, CELLI BR: Long term oxygen therapy. N. Engl. J. Med. (1995) 333:710-714.
61. O'BRIEN A, KAMAL I: Long term oxygen therapy use: audit of an Irish regional hospital. Proceedings of the American Thoracic Society Abstracts (2006) 3:A109.
62. MURCIANO D, AUBIER M, LECOCGUIC Y et al.: Effects of theophylline on diaphragmatic strength and fatigue in patients with chronic obstructive pulmonary disease. N. Engl. J. Med. (1984) 311:349-353.
63. CULPITT SV, DE MATOS C, RUSSELL RE et al.: Effect of theophylline on induced sputum inflammatory indices and neutrophil chemotaxis in COPD. Am. J. Respir. Crit. Care Med. (2002) 165:1371-1376.
64. POLSON JB, KRZANOWSKI JJ, GOLDMAN AL, SZENTIVANYI A: Inhibition of human pulmonary phosphodiesterase activity by therapeutic levels of theophylline. Clin. Exp. Pharmacol. Physiol. (1978) 5:535-539.
65. PAUWELS RA, JOOS GF: Characterization of the adenosine receptors in the airways. Arch. Int. Pharmacodyn. Ther. (1995) 329:151-160.
66. MASCALI JJ, CVIETUSA P, NEGRI J, BORISH L: Anti-inflammatory effects of theophylline: modulation of cytokine production. Ann. Allergy Asthma Immunol. (1996) 77:34-38.
67. ITO K, LIM S, CARAMORI G et al.: A molecular mechanism of action of theophylline: induction of histone deacerylase activity to decrease inflammatory gene expression. Proc. Natl. Acad. Sci. USA (2002) 99:8921-8926.
68. BERRY MJ, REJESKI WJ, ADAIR NE, ZACCARO D: Exercise rehabilitation and chronic obstructive pulmonary disease stage. Am. J. Respir. Crit. Care Med. (1999) 160:1248-1253.
69. LACASSE Y, WONG E, GUYATT GH, KING D, COOK DJ, COLDSTEIN RS: Meta-analysis of respiratory rehabilitation in chronic obstructive pulmonary disease. Lancet (1996) 348:1115-1119.
70. GUELL R, CASAN P, BELDA J et al.: Long-term effects of outpatient rehabilitation of COPD. A randomized trial. Chest (2000) 117:976-983.
71. GRIFFITHS TL, BURR ML, CAMPBELL IA et al.: Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomized controlled trial. Lancet (2000) 355:362-368.
72. POOLE PJ, CHACKO E, WOOD-BAKER RW, CATES CJ: Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev (2006) 25(1):CD002733.
73. WILLIAMS JH Jr, MOSER KM: Pneumococcal vaccine and patients with chronic lung disease. Ann. Intern. Med. (1986) 104:106-109.
74. CELLI BR, MACNEE W: Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur. Respir. J. (2004) 23(6):932-946.
75. SCHIPPER PH, MEYERS BF, BATTAFARANO RJ et al.: Outcomes after resection of giant emphysematous bullae. Ann. Thorac. Surg. (2004) 78(3):976-982.
76. FISHMAN A, MARTINEZ F, NAUNHEIM K et al.: A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N. Engl. J. Med. (2003) 348(21):2059-2073.
77. 1-antitrypsin deficiency. J. Thorac. Cardiovasc. Surg. (2004) 128:408-413.
78. CASSINA PC, TESCHLER H, KONIETZKO N, THEEGARTEN D, STAMATIS G: Two-year results after lung volume reduction surgery in α-1-antitrypsin deficiency versus smoker's emphysema. Eur. Respir. J. (1998) 12:1028-1032.
79. HOSENPUD JD, BENNETT LE, KECK BM, BOUCEK MM, NOVICK RJ: The registry of the International Society for Heart and Lung Transplantation: eighteenth official report - 2001. J. Heart Lung Transplant. (2001) 20:909-931.
80. MAURER JR, FROST AE, ESTENNE M et al.: International guidelines for the selection of lung transplant candidates. The International Society for Heart and Lung Transplantation, the American Thoracic Society, the American Society of Transplant Physicians, the European Respiratory Society. Transplantation (1998) 66:951-956.
81. AMERICAN THORACIC SOCIETY/EUROPEAN RESPIRATORY SOCIETY. American Thoracic Sociery/European Respiratory Society statement: Standards for the diagnosis and management of individuals with α-1-antitrypsin deficiency. Am. J. Respir. Crit. Care Med. (2003) 168:818-900.
82. SAINT S, BENT S, VITTINGHOFF E et al.: Antibiotics in chronic obstructive pulmonary disease exacerbations: a meta analysis. JAMA (1995) 273:957-960.
83. PELKONEN M, TUKIAINEN H, TERVAHAUTA M et al.: Pulmonary function, smoking cessation and 30 year mortality in middle aged Finnish men. Thorax (2000) 55:746-750.
84. STEY C, STEURER J, BACHMAN S, MEDIA TC, TRAMER MR. The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review. Eur. Respir. J. (2000) 16(2):253-262.
85. DECRAMER M, RUTTEN-VAN MOLKEN M, DEKHUIJZEN PN et al.: Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomized placebo-controlled trial. Lancet (2005) 365:1552-1560.
86. LANDBO C, PRESCOTT E, LANGE P et al: Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. (1999) 160:1856-1861.
87. YEH SS, DEGUZMAN B, KRAMER TK: Reversal of COPD-associated weight loss using the anabolic agent oxandrolone. Chest (2002) 122:421-428.
88. NAGAYA N, ITOH, T, MURAKAMI S et al.: Treatment of Cachexia with ghrelin in patients with COPD. Chest (2005) 128:1187-1193.
89. DI SEFANO A, CARAMORI G, OATES T et al.: Increased expression of nuclear factor-kappaβ in bronchial biopsies from smokers and patients with COPD. Eur. Resp. J. (2002) 20:556-563.
90. 2-induced bronchitis. Fundam. Clin. Pharmacol. (1993) 7(3-4):155-160.
91. YASUDA H, YAMAYA M, SASAKI T et al.: Carbocysteine reduces frequency of common colds and exacerbations in patients with chronic obstructive pulmonary disease. J. Am. Geriatr. Soc. (2006) 54:378-380.
92. FORONJY RF, MIROCHNITCHENKO O, PROPOKENKO O et al.: Superoxide dismutase expression attenuates cigarette smoke- or elastase-generated emphysema in mice. Am. J. Respir. Ctit. Care Med. (2006) 173:623-631.
93. KEATINGS BM, COLLINS PD, SCOTT DM et al.: Differences in interleukin-8 and tumor necrosis factor-α in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am. J. Respir. Crit. Care Med. (1996) 153:530-534.
94. DONNELLY LE, ROGERS DF: Therapy for chronic obstructive pulmonary disease in the 21st century. Drugs (2003) 63:1973-1998.
95. MAHLER DA, HUANG S, TABRIZI M, BELL GM: Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study. Chest (2004) 126:926-934.
96. KIPS JC, TAVERNIER JH, JOOS GF, PELEMAN RA, PAUWELS RA: The potential role of tumour necrosis factor α in asthma. Clin. Exp. Allergy (1993) 23:247-250.
97. SULKOWSKA M, SULKOWSKI S, TERLIKOWSKI S, NOWAK HF: Tumor necrosis factor-α induces emphysema-like pulmonary tissue rebuilding; changes in Type II alveolar epithelial cells. J. Pol. Pathol. (1997) 48:179-188.
98. DE GODOY I, DONAHOE M, CALHOUN WJ, MANCINO J, ROGERS RM: Elevated TNF-α production by peripheral blood monocytes of weight-losing COPD patients. Am. J. Respir. Crit. Care Med. (1996) 153:633-637.
99. VAN DER VAART H, KOETER GH, POSTMA DS et al.: First study of infliximab treatment in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. (2005) 172:465-469.
100. KEANE J, GERSHON S, WISE RP et al.: Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N. Engl. J. Med. (2001) 345:1098-1104.
101. GOMPERTZ S, O'BRIEN C, BAYLEY DL et al.: Changes in bronchial inflammation during acute exacerbations of chronic bronchitis. Eur. Respir. J. (2001) 17:1112-1119.
102. BIRKE FW, MEADE CH, ANDERSKEWITZ R, SPECK GA, JENNEWEIN HM: In vitro and in vivo pharmacological characterization of BILL 284, a novel and potent leukotriene B(4) receptor antagonist. J. Pharmacol. Exp. Ther. (2001) 297:458-466.
103. MOLFINO NA: Drugs in clinical development for chronic obstructive pulmonary disease. Respiration (2005) 72:105-112.
104. GOMPERTZ S, STOCKLEY RA: A randomized, placebo-controlled trial of a leukotriene synthesis inhibitor in patients with COPD. Chest (2002) 122(1):289-294.
105. SPIROPOULOS K, TRAKADA G, NIKOTAOU E et al.: Endothelin-1 levels in the pathophysiology of chronic obstructive pulmonary disease and bronchial asthma. Respir. Med. (2003) 97:983-989.
106. TRAKADA G, MARANGOS M, SPIROPOULOS K: Mechanisms of endothelin-1 elevation in chronic obstructive pulmonary disease patients with nocturnal oxyhemoglobin desaturation. Respiration (2001) 68:134-139.
107. BENNETT WD, ZEMAN KL, FOY C et al.: Effect of aerosolized uridine-5′ triphosphate on mucociliary clearance in mild chronic bronchitis. Am. J. Respir. Crit. Care Med. (2001) 164:302-306.
108. KELLERMAN D, BENNETT W, ZEMAN K: Dose response relationship of P2Y2 agonist INS365 of mucociliary clearance in smokers. J. Allergy Clin. Immunol. (2001) 107:S164.
109. JOOS GF, DE SWERT KO, PAUWELS RA: Airway inflammation and tachykinins: prospects for the development of tachykinin receptor antagonists. Eur. J. Pharmacol. (2001) 163:A628.
110. ANTHES JC, CHAPMAN RW, RICHARD C et al.: SCH 206272: a potent, orally active tachykinin NK(1), NK(2), and NK(3) receptor antagonist. Eur. J. Pharmacol. (2002) 450(2):191-202.
111. KRAAN J, VINK-KLOOSTER H, POSTMA DS: The NK-2 receptor antagonist SR 48968C does not improve adenosine hyperresponsiveness and airway obstruction in allergic asthma. Clin. Exp. Allergy (2001) 31(2):274-278.
112. VAN SCHOOR J, JOOS GF, CHASSON BL, BROUARD RJ, PAUWELS RA: The effect of the NK2 tachykinin receptor agonist SR 48968(saredutant) on neurokinin A-induced bronchoconstriction in asthmatics. Eur. Respir. J. (1998) 12(1):17-23.
113. MYOU S, FUJIMURA M, KAMIO Y et al.: Bronchodilator effect of inhaled olprinone, a phosphodiesterase 3 inhibitor, in asthmatic patients. Am. J. Respir. Crit. Care Med. (1999) 160:817-820.
114. GIEMBYCZ M: Dual specificity phosphodiesterase inhibitors in COPD. The Science of COPD: opportunities for combination therapy (2006) University of Nebraska Medical Center. P21.
115. TORPHY TJ: Phophodiesterase isoenzymes: molecular targets for novel anti-asthma agents. Am. J. Respir. Crit. Care Med. (1998) 157:351-370.
116. STURTON G, FITZGERALD M: Phosphodiesterase 4 inhibitors for the treatment of COPD. Chest (2002) 121:192S-196S.
117. COMPTON CH, GUBB J, CEDAR E et al.: Ariflo (SB 207499), a second generation oral PDE4 inhibitor, improves quality of life in patients with COPD (abstract). Am. J. Respir. Crit. Care. Med. (1999) 195(Suppl.):A522.
118. COMPTON CH, BUGG J, CEDER E et al.: The efficacy of Ariflo (SB 207499), a second generation PDE 4 inhibitor, in patients with COPD (abstract). Am. J. Respir. Crit. Care Med. (1999) 195(Suppl.):A806.
119. RENNARD SI, SCHACHTER N, STREK M et al.: Cilomilast for COPD: Results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4. Chest (2006) 129:56-66.
120. RABE KF, BATEMAN ED, O'DONNELL D et al.: Roflumilast - an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomized controlled trial. Lancet (2005) 366:563-571.
121. LIPWORTH BJ: Phophodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet (2005) 365:167-175.
122. GROOTENDORST DC, TAWW SA, BENSCHOP N, STERK RJ, HIEMSTRA PS, RABE KF: Efficacy of the novel phosphodiesterase-4 inhibitor BAY 19-8004 on lung function and airway inflammation in asthma and chronic obstructive pulmonary disease (COPD). Pulm. Pharmacol. Ther. (2003) 16(6):341-347.
123. HOPPMAN J, KUSS H, HOFGEN N et al.: ELB526, a new selective PDE4-inhibitor for topical administration with a large safety margin. Proceedings of the American Thoracic Society, Ahstracts (2006) 3:A117.
124. FINLAY GA, RUSSELL KJ, MCMAHON KJ et al.: Elevated levels of matrix metalloproteinases in bronchoalveolar lavage fluid of emphysematous patients. Thorax (1997) 52:502-506.
125. JOOS L, HE J-Q, SHEPERDSON MB et al.: The role of matric metalloproteinase polymorphisms in the rate of deline in lung function. Hum. Mol. Genet. (2002) 11:569-576.
126. OHNISHI K, TAKAGI M, KUROKAWA Y et al.: Matrix metalloproteinase-mediated extracellular matrix protein degradation in human pulmonary emphysema. Lab. Invest. (1998) 78:1077-1087.
127. RUSSELL RE, CULPITT SV, DEMATOS C et al.: Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am. J. Respir. Cell. Mol. Biol. (2002) 26:602-609.
128. RUSSELL RE, THORLEY A, CULPITT SV et al.: Alveolar macrophage-mediated elastolysis: roles of matrix metalloproteinases, cysteine, and serine proteases. Am. J. Pbysiol. Lung Cell. Mol. Physiol. (2002) 283:L867-L873.
129. MERCER PF, SHUTE JK, BHOWMIK A et al.: MMP-9, TIMP-1 and inflammatory cells in sputum from COPD patients during exacerbation. Respir. Res. (2005) 6:151.
130. NO AUTHORS LISTED: Marimastat: BB 2516, TA 2516. Drugs R D (2003) 4:198-203.
131. PEMBERTON PA, CANTWELL JS, KIM KM et al.: An inhaled matrix metalloprotease inhibitor prevents cigarette smoke-induced emphysema in the mouse. COPD (2005) 2:303-310.
132. OHBAYASHI H: Novel neutrophil elastase inhibitors as a treatment for neutrophil-predominant inflammatory lung diseases. Drugs (2002) 5:910-923.
133. KURAKI T, ISHIBASHI M, TAKAYAMA M et al.: A novel oral neutrophil elastase inhibitor (ONO06818) inhibits human neutrophil elastase-induced emphysema in rats. Am. J. Respir. Crit. Care Med. (2002) 166:496-500.
134. LUISETTI M, STURANI CL, SELLA D et al.: MR889, a neutrophil elastase inhibitor, in patients with chronic obstructive pulmonary disease: a double-blind, randomized, placebo-controlled clinical trial. Eur. Respir. J. (1996) 9:1482-1486.
135. TOMEE JF, KOETER CH, HIEMSTRA PS et al. Secretory leukoprotease inhibitor: a native antimicrobial protein presenting a new therapeutic option? Thorax (1998) 53:114-116.
136. MCELVANEY NG, DOUJAIJI B, MOAN MJ et al.: Pharmacokinetics of recombinant secretory leukoprotease inhibitor aerosolized to normals and individuals with cystic fibrosis. Am. Rev. Respir. Dis. (1993) 148:1056-1060.
137. KYRIAKIS JM, AVRUCH J: Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol. (2001) 81:807-869.
138. UNDERWOOD DC, OSBORN RR, BOCHNOWICZ. S et al.: SB239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cyrokines, MMP-9, and fibrosis in lung. Am. J. Physiol. Lung Cell. Mol. Physiol. (2000) 279 L895-L902.
139. MASSARO GD, MASSARO D: Retinoic acid treatment abrogates elastase-induced pulmonary emphysema in rats. Nat. Med. (1997) 3:675-677.
140. MARCH TH, BOWEN LE, FINCH GL, NIKULA KJ, WAYNE BJ, HOBBS CH: Effects of strain and treatment with inhaled all-trans-retinoic acid on cigarette smoke-induced pulmonary emphysema in mice. COPD (2005) 2:289-302.
141. MAO JT, GOLDIN JG, DERMAND J et al.: A pilot study of all-trans-retinoic acid for the treatment of human emphysema. Am. J. Respir. Crit. Care Med. (2002) 165:718-723.
142. MAO JT, TASHKIN DP, BELLONI PN et al.: All-trans retinoic acid modulates the balance of matrix matalloprotienase-9 and tissue inhibitor of metalloproteinase-1 in patients with emphysema. Chest (2003) 124:1724-1732.
143. TUDER RM, PETRACHE I, ELIAS JA et al.: Apoptosis and emphysema: the missing link. Am. J. Respir. Cell Mol. Biol. (2003) 29:551-554.
144. KASAHARA Y, TUDER RM, COOL CD et al.: Endothelial cell death and decreased expression of vascular endothelial growth factor receptor 2 in emphysema. Am. J. Respir. Crit. Care Med. (2001) 17:946-953.
145. KASAHARA Y, TUDER RM, TARASEVICIENE-STERWART L et al.: Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J. Clin. Invest. (2000) 106:1311-1319.
146. KANAZAWA H, YOSHIKAWA J: Elevated oxidative stress and reciprocal reduction of vascular endothelial growth factor levels with severity of COPD. Chest (2005) 128:3191-3197.
147. KRANENBURG AR, DE BOER WI, ALAGAPPAN VK et al.: Enhanced bronchial expression of vascular endothelial growth factor and receptors (Flk-1 and Flt-1) in patients with chronic obstructive pulmonary disease. Thorax (2005) 60:106-113.
148. WAN IY, TOMA TP, GEDDES DM et al.: Bronchoscopic lung volume reduction for end-stage emphysema: report on the first 98 patients. Chest (2006) 129:518-526.